A 12-week, Randomized, Single-blind, Placebo-controlled, Multi-centre, Parallel Group, Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 After 4 and 12-weeks of Treatment in Patients With Coronary Artery Disease (CAD)
Phase of Trial: Phase II
Latest Information Update: 31 Dec 2018
At a glance
- Drugs AZD 5718 (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms FLAVOUR
- Sponsors AstraZeneca
- 19 Dec 2018 Planned primary completion date changed from 21 Dec 2018 to 1 Jul 2019.
- 23 Oct 2018 Planned End Date changed from 31 May 2019 to 1 Jul 2019.
- 23 Oct 2018 Planned primary completion date changed from 20 Dec 2018 to 21 Dec 2018.